CCMDS/AML Preliminary Agenda 2024
Friday September 20, 2024
Fairmont Palliser Hotel, Calgary, AB
| 7:30 am – 8:30 am | Breakfast – Oak Room |
| 8:30 am – 8:35 am | CCMDS/AML Welcome – Dr. Michelle Geddes |
| 8:35 am – 12:20 pm | Morning Sessions and Introductions – Crystal Ballroom |
| 8:35 am – 9:00 am | Prognostication – Molecular Testing and What is Next – Genomes and Transcriptomes and Clinical Relevance – Dr. Rafael Bejar |
| 9:00 am – 9:25 am | DDX4 Mutation Role in Leukemia Pathogenesis and Role of Familial Testing – Dr. Lucy Godley |
| 9:25 am – 9:50 am | Anemia Pathophysiology in MDS – Dr. Sophie Park |
| 9:50 am – 10:15 am | Optical Genome Mapping and Role in AML and MDS – With Cases – Dr. Adam Smith |
| 10:15 am – 10:35 am | Panel with case(s) – Dr. R. Bejar, Dr. L. Godley, Dr. S. Park, Dr. A. Smith |
| 10:35 am – 10:55 am | Refreshment Break – Oak Room |
| 10:55 am – 11:20 am | SF3B1 Mutations Provide Genetic Vulnerability to Copper ionophores in Human Acute Myeloid Leukemia – Dr. Céline Moison |
| 11:20 am – 11:50 am | CAN MDS Platform and Research Initiatives – Dr. Brett Houston |
| 11:50 am – 12:20 pm | MDS Registry Update and Initiatives – Dr. Rena Buckstein |
| 12:20 pm – 1:20 pm | Lunch – Alberta Ballroom |
| 1:20 pm – 5:15 pm | Afternoon Sessions and Introductions – Crystal Ballroom |
| 1:25 pm – 1:30 pm | Introduction to the Carolyne Delage Investigator Award |
| 1:30 pm – 1:35 pm | Carolyne Delage Young Investigators Award – Presented by Dr. Brian Leber |
| 1:35 pm – 2:05 pm | Epigenetics and Response to Therapy with HMAs – Dr. Aly Karsan |
| 2:05 pm – 2:35 pm | Impact of IPSS-M in Treatment Decisions and Which Lower Risk Patients Should We Treat Aggressively – Dr. Rami Komrokji |
| 2:35 pm – 3:05 pm | Fitness for Treatment Decisions in MDS and AML – Dr. Rena Buckstein |
| 3:05 pm – 3:25 pm | Refreshment Break – Oak Room |
| 3:25 pm – 3:55 pm | CHIP/CCUS/ICUS– Dr. Rafael Bejar |
| 3:55 pm – 4:25 pm | Updates on Clinical Trials Recently Released in MDS: Verona, Sabatolimab Imetelstat – Dr. Sophie Park |
| 4:25 pm – 4:40 pm | Clearpath Update – Dr. Heather Leitch |
| 4:40 pm – 5:15 pm | Panel Discussion:
Panelists: Dr. R. Bejar, Dr. H. Leitch, Dr. S. Park |
| 5:15 pm – 5:20 pm | Closing Remarks |
| 5:20 pm – 7:20 pm | CCMDS AML Welcome Reception – Oak Room |
Saturday September 21, 2024
Fairmont Palliser Hotel, Calgary, AB
| 7:30 am – 8:30 am | Breakfast – Crystal Ballroom |
| 8:30 am – 8:35 am | Morning Welcome |
| 8:35 am – 11:50 am | Morning Sessions and Introductions – Crystal Ballroom |
| 8:35 am – 9:05 am | Biologic Markers of Response and Resistance to Azacitine and Venetoclax for Newly Diagnosed AML – Dr. Keith Pratz |
| 9:05 am – 9:35 am | FLT-3 Biology and Optimal Role of FLT3 Inhibitors in AML – Dr. Alexander Perl |
| 9:35 am – 10:05 am | Use of Novel Agents in AML in the Canadian Context – Current and Coming Agents – Dr. Brian Leber |
| 10:05 am – 10:20 am | Refreshment Break – Oak Room |
| 10:20 am – 10:45 am | Application of MRD Monitoring in Clinical Practice – Dr. Michael Heuser |
| 10:45 am – 11:10 am | MRD-Driven Therapy of AML – Dr. Nigel Russell |
| 11:10 am – 11:30 am | Canadian Perspective on MRD Use and Research Projects/Results – Dr. Steven Chan |
| 11:30 am – 11:50 am | Panel Discussion – Dr. S. Chan, Dr. M. Heuser, Dr. N. Russell |
| 11:50 am – 12:50 pm | Lunch – Meet the Experts – Alberta Ballroom |
| 12:50 pm – 5:05 pm | Afternoon Sessions and Introductions – Crystal Ballroom |
| 12:50 pm – 12:55 pm | Introduction to the Stephen Couban Keynote Lecture |
| 12:55 pm – 1:40 pm | Stephen Couban Keynote Lecture: The Devil p53 in AML and MDS – Dr. David Sallman |
| 1:40 pm – 1:50 pm | Question Period |
| 1:50 pm – 2:05 pm | Refreshment Break – Oak Room |
| 2:05 pm – 2:35 pm | Genetic Classification of AML – The Vancouver Experience, Data on RNA Seq – Dr. Ryan Stubbins |
| 2:35 pm – 3:05 pm | Future Role for MicroRNA in AML Disease Classification – Dr. Florian Kuchenbauer |
| 3:05 pm – 3:35 pm | Relapsed/Refractory AML for Fit and Unfit AML – What Now and What is Coming, Including Ven/aza Failures – Dr. Michael Heuser |
| 3:35 pm – 3:55 pm | Refreshment Break – Oak Room |
| 3:55 pm – 4:05 pm | Canadian AML Registry – Dr. Kristjan Paulson |
| 4:05 pm – 4:15 pm | CTTG Basket Study Update – Dr. Lynn Savoie |
| 4:15 pm – 4:40 pm | Updates on the NHLBI MDS Natural History Study and Applying Machine Learning to MDS – Dr. Mikkael Sekeres |
| 4:40 pm – 5:05 pm | Panel Discussion: 3 cases (5 min each and discussion) Panelists: Dr. S. Chan, Dr. D. Sallman, Dr. M. Sekeres |
| 5:05 pm – 5:10 pm | Closing Remarks |
Sunday September 22, 2024
Fairmont Palliser, Calgary, AB
| 7:30 am – 8:30 am | Breakfast – Oak Room |
| 8:30 am – 12:00 pm | Morning Session – Crystal Ballroom |
| 8:30 am – 8:35 am | Morning Welcome and Session Introduction |
| 8:35 am – 9:00 am | Optimal Role of Familial Testing in MDS/AML – Who to Test and Novel Mutations – Dr. Lucy Godley |
| 9:00 am – 9:25 am | Optimal Management of CMML – Role of HMA, Venetoclax, Novel Agents – Dr. Mikkael Sekeres |
| 9:25 am – 9:50 am | Transplant Decisions in the Era of the IPSS-M – Dr. Rami Komrokji |
| 9:50 am – 10:15 am | Optimal Management of Secondary AML – Dr. Nigel Russell |
| 10:15 am – 10:35 am | Panel with Cases – Dr. L. Godley, Dr. N. Russel, Dr. M. Sekeres |
| 8:30 am – 10:30 am | Nursing Session – Oval Room |
| 8:30 am – 8:40 am | Morning Welcome and Session Introduction – Ms. Cindy Murray |
| 8:40 am – 9:10 am | Case introduction & Diagnostic Work-Up – Ms. Baljit Randhawa & Ms. Ashley Boudreau |
| 9:10 am – 9:40 am | Practical Insights for Nurses: Navigating Risk Assessment and Genetic Testing in Hematologic Malignancies – Ms. Janet Malcolmson |
| 9:40 am – 9:50 am | Prognosis & Treatment Recommendations – Ms. Cindy Murray |
| 9:50 am – 10:20 am | Monitoring Treatment Response – Dr. Etienne Mahe |
| 10:20 am – 10:30 am | Questions & Wrap-Up |
| 10:35 am – 10:55 am | Refreshment Break – Oak Room |
| Morning Session Cont. – Crystal Ballroom | |
| 10:55 am – 11:25 am | Maintenance Therapy Post BMT – Dr. Tobias Berg |
| 11:25 am – 11:55 am | Updates in PNH Biology and Management – Dr. Monika Oliver |
| 11:55 am – 12:20 pm | VEXAS Syndrome – A New Entity in Hematology With Bone Marrow Failure – Dr. Kareem Jamani |
| 12:20 pm | Closing Remarks |